Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Here's Why Merck (MRK) is a Strong Value Stock
10:41am, Thursday, 20'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
09:45am, Thursday, 20'th Nov 2025
The pharmaceutical giant's post-Keytruda plans continue to take shape.
Merck & Co., Inc. $MRK Shares Acquired by 17 Capital Partners LLC
05:40am, Thursday, 20'th Nov 2025
17 Capital Partners LLC lifted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 13.9% in the second quarter, according to the company in its most recent filing with the Securities and Exch
Artisan Partners Limited Partnership Sells 26,500 Shares of Merck & Co., Inc. $MRK
04:26am, Thursday, 20'th Nov 2025
Artisan Partners Limited Partnership cut its position in Merck and Co., Inc. (NYSE: MRK) by 2.0% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
01:23pm, Wednesday, 19'th Nov 2025
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in a
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
01:05pm, Wednesday, 19'th Nov 2025
In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
11:56am, Wednesday, 19'th Nov 2025
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Healthcare Rotation Underway: 3 Stocks Leading the Charge
08:25am, Wednesday, 19'th Nov 2025
Is the artificial intelligence revolution hitting its first roadblock? For the first time since the AI boom began in 2023, the industry is starting to feel the weight of expectations, and many of the
Merck's oral HIV treatment meets main goal in late-stage study
06:50am, Wednesday, 19'th Nov 2025
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything
04:59pm, Tuesday, 18'th Nov 2025
In one of the most decisive strategic moves in the biotech sector this year, pharmaceutical titan Merck & Co. NYSE: MRK has committed a formidable $9.2 billion in cash to acquire Cidara Therapeutics
Drug Giant Merck Breaks Out Past New Buy Point; CME, Marathon Eye Entries
02:43pm, Tuesday, 18'th Nov 2025
Dow Jones drug giant Merck is breaking out past its latest buy point as the stock market volatility continues Tuesday.
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition
12:42pm, Tuesday, 18'th Nov 2025
Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (Cp
Dow Drops 516 Points on Dismal Home Depot Earnings
12:09pm, Tuesday, 18'th Nov 2025
All three major benchmarks are lower this afternoon, as investors grapple with fading AI optimism, Big Tech losses, and Bitcoin (BTC) weakness
